Tag: epi therapeutics and diagnostics market

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Value Growth And Long-Term Outlook

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has demonstrated significant expansion in recent years. It is anticipated to increase from $6.11 billion in 2025 to $6.55 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.1%. This historical development can be attributed to the rising occurrence of chronic pancreatitis, heightened awareness surrounding digestive ailments, constrained access to specialized diagnostic methods, the adoption of nutritional supplements, and the expansion of home healthcare offerings.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is set to experience substantial expansion in the upcoming years. It is forecast to grow to $8.97 billion in 2030, achieving a compound annual growth rate (CAGR) of 8.2%. This projected increase is attributed to several factors, including advancements in personalized enzyme therapies, the integration of artificial intelligence in diagnostics, a growing need for non-invasive imaging techniques, the expansion of telehealth services, and an increasing focus on patient-centric nutritional management. Notable trends for the forecast period encompass advanced pancreatic enzyme replacement therapies, the development of point-of-care diagnostic solutions, personalized nutritional management programs, non-invasive imaging techniques specifically for EPI, and the wider integration of telehealth into EPI management.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=12992&type=smp&name=Exocrine%20Pancreatic%20Insufficiency%20%28EPI%29%20Therapeutics%20And%20Diagnostics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Catalysts And Demand Drivers

The rising prevalence of diabetes is projected to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market moving forward. Diabetes is defined as a long-term metabolic condition marked by persistently elevated blood sugar levels (hyperglycemia), stemming from the body’s insufficient insulin production or ineffective insulin utilization. Pancreatic enzyme replacement therapy (PERT), a component of EPI treatment, aids in enhancing nutrient absorption and can also improve glycemic control in individuals with both diabetes and EPI. As an illustration, in June 2024, data from The National Health Service (NHS England), a publicly funded UK healthcare system, revealed that the count of individuals identified with pre-diabetes in England climbed to 3,615,330 in 2023, representing an 18% increase from 3,065,825 in 2022. Furthermore, for those under 40, pre-diabetes cases saw a substantial increase of almost 25%, rising from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing population affected by diabetes is a key factor propelling the development of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segment Breakdown: Which Categories Lead On Revenue?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends Shaping Long-Term Demand

Key companies active in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are employing a strategic alliance approach to boost technology integration and expand their market presence. A strategic partnership typically describes a collaborative relationship where two or more organizations combine their assets, expertise, and endeavors to achieve mutual goals. For example, in February 2023, Codexis, Inc., a US-based protein engineering company, and Nestlé Health Science, a Switzerland-based science of nutrition company, announced the interim results from their Phase 1 clinical trial of CDX-7108, an experimental treatment designed for exocrine pancreatic insufficiency (EPI). The outcomes from this Phase 1 trial lay the groundwork for further research that could significantly enhance treatment possibilities for patients living with EPI.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Leading Players And Competitive Positioning

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd

View The Full Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:

https://thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Geographic Analysis: Where Is Demand Rising Fastest?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics has experienced robust expansion in recent years. Projected to rise from $6.11 billion in 2025 to $6.55 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 7.1%. Historical expansion has been driven by factors such as a higher incidence of chronic pancreatitis, growing public awareness of digestive health issues, restricted availability of specialized diagnostic tools, increased use of nutritional supplements, and the broadening reach of home healthcare services.

The market for exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics is projected to experience robust expansion in the coming years. By 2030, its value is anticipated to reach $8.97 billion, driven by a compound annual growth rate (CAGR) of 8.2%. This forecasted growth is influenced by progress made in customizing enzyme therapies, the incorporation of artificial intelligence into diagnostic tools, an increased need for imaging methods that are non-invasive, the broadening of telehealth services, and a heightened emphasis on nutrition management tailored to individual patients. Key developments shaping this period include improved forms of pancreatic enzyme replacement therapy, rapid diagnostic tools usable at the point of care, customized nutritional care plans, imaging techniques that avoid invasive procedures for EPI, and the widespread adoption of telehealth within EPI treatment protocols.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth Drivers: What Factors Are Accelerating Expansion?

The rising prevalence of diabetes is anticipated to drive expansion in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the coming period. Diabetes is defined as a chronic metabolic condition marked by sustained high blood sugar levels (hyperglycemia) over an extended timeframe. This disorder arises when the body fails to generate sufficient insulin or cannot utilize the insulin it produces effectively. EPI treatment, primarily through pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption in individuals with both diabetes and EPI. Additionally, it may support better glycemic control in diabetic patients. For example, in June 2024, data from The National Health Service (NHS England), a publicly funded healthcare system in the UK, revealed that in 2023, the count of individuals identified with pre-diabetes in England climbed to 3,615,330, representing an 18% rise from 3,065,825 in 2022. Moreover, among those under 40, cases surged by nearly 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing number of diabetes cases is fueling the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

The growing frequency of gastrointestinal disorders is expected to boost the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market moving forward. Gastrointestinal diseases encompass a range of medical conditions impacting the gastrointestinal tract, which includes organs involved in digestion. EPI therapeutics and diagnostics are essential for managing these diseases by targeting the root enzyme deficiency and facilitating proper nutrient digestion. They play a key role in gastrointestinal disease management by correcting enzyme shortages and aiding digestive processes. As an illustration, in June 2023, Crohn’s and Colitis Canada, a non-profit organization based in Canada, reported that over 322,600 Canadians were estimated to be living with inflammatory bowel diseases (IBD) in 2023, accounting for roughly 0.82% of the population. With the ongoing rise in IBD prevalence, projections indicate that approximately 470,000 Canadians will have IBD by 2035, equating to about 1.1% of the population, or one in every 91 individuals nationwide. Thus, the escalating incidence of gastrointestinal diseases is anticipated to drive growth in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segment Analysis: What Are The Major Market Categories?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends: What Is Shaping Future Industry Growth?

Major players within the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are actively leveraging a strategic partnership approach to drive better technology integration and broaden their market presence. This type of arrangement generally involves a collaborative alliance between multiple organizations, where they pool their resources, specialized knowledge, and collective efforts to achieve shared goals or objectives. A case in point is February 2023, when Codexis, Inc., a protein engineering firm based in the United States, joined forces with Nestlé Health Science, a Swiss company focused on nutritional science, to release interim findings from their Phase 1 clinical trial for CDX-7108—an investigational therapy designed to manage exocrine pancreatic insufficiency (EPI). These outcomes from the Phase 1 trial lay a solid foundation for subsequent investigations that could potentially lead to significant enhancements in treatment options for individuals dealing with EPI.

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Leading Companies Driving Competitive Growth

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd

Access The Complete Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Leading Geography: Which Region Generates The Most Revenue?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market During The 2026–2030 Period?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has seen strong growth in recent years. It is forecast to increase from $6.11 billion in 2025 to $6.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. The expansion observed historically stems from an increasing prevalence of chronic pancreatitis, growing awareness about digestive disorders, limited access to specialized diagnostics, the adoption of nutritional supplements, and the rise in home healthcare services.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is projected to experience robust expansion over the coming years. This market is anticipated to reach a valuation of **$8.97 billion by 2030**, exhibiting a compound annual growth rate (CAGR) of **8.2%**. Several factors are set to drive this growth during the forecast period, including progress in personalized enzyme therapies, the incorporation of AI into diagnostics, an increasing need for non-invasive imaging techniques, the proliferation of telehealth services, and an intensified emphasis on nutritional management centered around the patient. Key developments expected within this timeframe encompass sophisticated pancreatic enzyme replacement therapies, diagnostic solutions available at the point of care, customized nutritional management programs, non-invasive imaging methods specifically for EPI, and the broader adoption of telehealth in EPI care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What Major Growth Factors Are Impacting The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

The increasing number of people diagnosed with diabetes is anticipated to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Diabetes is a chronic metabolic condition marked by persistently elevated blood sugar levels (hyperglycemia), stemming from the body’s inability to produce adequate insulin or to effectively utilize the insulin it does produce. Exocrine pancreatic insufficiency (EPI) therapy, including pancreatic enzyme replacement therapy (PERT), can aid in enhancing nutrient absorption and improving glycemic control for individuals with diabetes and EPI. For instance, as reported by The National Health Service (NHS England) in June 2024, the count of individuals identified with pre-diabetes in England reached 3,615,330 in 2023, signifying an 18% rise from 3,065,825 in 2022. Additionally, among those younger than 40, cases increased by nearly 25%, growing from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising prevalence of diabetes is a significant factor driving the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The rising occurrence of gastrointestinal diseases is projected to stimulate the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market going forward. Gastrointestinal diseases refer to a variety of medical conditions that impact the gastrointestinal tract, which comprises the organs responsible for the digestive process. Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics play a vital role in the management of gastrointestinal diseases by addressing underlying enzyme deficiencies and facilitating proper nutrient digestion. For example, in June 2023, Crohn’s and Colitis Canada, a non-profit organization located in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, representing approximately 0.82% of the population. As the prevalence of IBD continues, it is estimated that around 470,000 Canadians will be affected by IBD by 2035, which would constitute approximately 1.1% of the population, or 1 in every 91 people in the country. Therefore, the increasing incidence of gastrointestinal diseases is expected to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

What Segment Types Are Included In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Analysis?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Which Trends Are Guiding The Development Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Key companies operating within the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are adopting a strategic partnership model to enhance technology integration and expand their market reach. A strategic partnership generally describes a collaborative relationship between two or more entities that combine their resources, specialized knowledge, and efforts to achieve shared objectives. For example, in February 2023, Codexis, Inc., a US-based protein engineering company, and Nestlé Health Science, a Switzerland-based science of nutrition, disclosed interim results from their Phase 1 clinical trial of CDX-7108, an investigational therapy developed to treat exocrine pancreatic insufficiency (EPI). The outcomes from this Phase 1 trial create a pathway for future studies, which could considerably improve treatment options for individuals suffering from EPI.

Who Are The Prominent Players Across The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd

Access The Complete Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Which Region Is The Dominant Market In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026, By The Business Research Company

Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Exocrine Pancreatic Insufficiency Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Acute Pancreatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Projected To Reach By 2030?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market has experienced robust growth in recent years. This market is projected to expand from $6.11 billion in 2025 to $6.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. Its historical growth can be attributed to elements such as the increasing prevalence of chronic pancreatitis, a heightened awareness of digestive disorders, limited access to specialized diagnostics, the adoption of nutritional supplements, and the expansion of home healthcare services.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $8.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. The projected increase during this period is driven by progress in personalized enzyme therapies, the incorporation of AI into diagnostics, an increasing need for non-invasive imaging, the widening availability of telehealth services, and a heightened emphasis on patient-focused nutritional management. Key trends expected during the forecast timeframe encompass sophisticated pancreatic enzyme replacement therapies, point-of-care diagnostic options, tailored nutritional management plans, non-invasive imaging methods for EPI, and the integration of telehealth into EPI management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What Significant Factors Are Influencing The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Expansion?

The anticipated rise in the number of individuals suffering from diabetes is projected to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes is defined as a long-term metabolic ailment characterized by persistently elevated blood sugar levels (hyperglycemia), stemming from the body’s inability to synthesize sufficient insulin or its inefficient utilization. EPI treatment, specifically pancreatic enzyme replacement therapy (PERT), is effective in enhancing nutrient absorption and can also improve glycemic control for those with both diabetes and EPI. For example, in June 2024, data from The National Health Service (NHS England), a publicly funded UK healthcare system, revealed that in 2023, the count of individuals identified with pre-diabetes by the NHS in England increased to 3,615,330, representing an 18% surge from 3,065,825 in 2022. Furthermore, among individuals below 40 years old, cases saw a nearly 25% rise, escalating from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing population affected by diabetes is a significant force driving the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The increasing occurrence of gastrointestinal illnesses is expected to stimulate the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Gastrointestinal diseases encompass a range of medical conditions impacting the digestive system, which includes the organs vital for food processing. These therapeutics and diagnostics for Exocrine pancreatic insufficiency (EPI) are essential for managing gastrointestinal diseases by addressing underlying enzyme deficiencies and facilitating proper nutrient digestion. As an illustration, in June 2023, Crohn’s and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting approximately 0.82% of the population. With the ongoing spread of IBD, it is predicted that around 470,000 Canadians will be affected by IBD by 2035, amounting to roughly 1.1% of the population, or 1 in every 91 people in the country. Thus, the escalating incidence of gastrointestinal diseases is poised to boost the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

How Are Segments Identified Within The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segment Framework?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Which Trends Are Impacting The Progress Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Leading companies active in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are employing a strategic partnership strategy to boost technology integration and expand their market reach. A strategic partnership typically denotes a collaborative relationship between two or more entities, where they combine their assets, expertise, and endeavors to achieve shared goals or objectives. For instance, in February 2023, Codexis, Inc., a US-based protein engineering company, along with Nestlé Health Science, a Switzerland-based science of nutrition, disclosed preliminary results from their Phase 1 clinical trial of CDX-7108, an experimental therapy designed to treat exocrine pancreatic insufficiency (EPI). The outcomes from this Phase 1 trial set the stage for further studies that could significantly enhance treatment options for patients affected by EPI.

Who Are The Companies Competing Within The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd

Get The Full Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Which Region Dominates The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market By Market Share?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026, By The Business Research Company

Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Exocrine Pancreatic Insufficiency Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Acute Pancreatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Projected To Reach By 2030?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market has experienced robust growth in recent years. This market is projected to expand from $6.11 billion in 2025 to $6.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. Its historical growth can be attributed to elements such as the increasing prevalence of chronic pancreatitis, a heightened awareness of digestive disorders, limited access to specialized diagnostics, the adoption of nutritional supplements, and the expansion of home healthcare services.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $8.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. The projected increase during this period is driven by progress in personalized enzyme therapies, the incorporation of AI into diagnostics, an increasing need for non-invasive imaging, the widening availability of telehealth services, and a heightened emphasis on patient-focused nutritional management. Key trends expected during the forecast timeframe encompass sophisticated pancreatic enzyme replacement therapies, point-of-care diagnostic options, tailored nutritional management plans, non-invasive imaging methods for EPI, and the integration of telehealth into EPI management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What Significant Factors Are Influencing The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Expansion?

The anticipated rise in the number of individuals suffering from diabetes is projected to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes is defined as a long-term metabolic ailment characterized by persistently elevated blood sugar levels (hyperglycemia), stemming from the body’s inability to synthesize sufficient insulin or its inefficient utilization. EPI treatment, specifically pancreatic enzyme replacement therapy (PERT), is effective in enhancing nutrient absorption and can also improve glycemic control for those with both diabetes and EPI. For example, in June 2024, data from The National Health Service (NHS England), a publicly funded UK healthcare system, revealed that in 2023, the count of individuals identified with pre-diabetes by the NHS in England increased to 3,615,330, representing an 18% surge from 3,065,825 in 2022. Furthermore, among individuals below 40 years old, cases saw a nearly 25% rise, escalating from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing population affected by diabetes is a significant force driving the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The increasing occurrence of gastrointestinal illnesses is expected to stimulate the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Gastrointestinal diseases encompass a range of medical conditions impacting the digestive system, which includes the organs vital for food processing. These therapeutics and diagnostics for Exocrine pancreatic insufficiency (EPI) are essential for managing gastrointestinal diseases by addressing underlying enzyme deficiencies and facilitating proper nutrient digestion. As an illustration, in June 2023, Crohn’s and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting approximately 0.82% of the population. With the ongoing spread of IBD, it is predicted that around 470,000 Canadians will be affected by IBD by 2035, amounting to roughly 1.1% of the population, or 1 in every 91 people in the country. Thus, the escalating incidence of gastrointestinal diseases is poised to boost the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

How Are Segments Identified Within The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segment Framework?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Which Trends Are Impacting The Progress Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Leading companies active in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are employing a strategic partnership strategy to boost technology integration and expand their market reach. A strategic partnership typically denotes a collaborative relationship between two or more entities, where they combine their assets, expertise, and endeavors to achieve shared goals or objectives. For instance, in February 2023, Codexis, Inc., a US-based protein engineering company, along with Nestlé Health Science, a Switzerland-based science of nutrition, disclosed preliminary results from their Phase 1 clinical trial of CDX-7108, an experimental therapy designed to treat exocrine pancreatic insufficiency (EPI). The outcomes from this Phase 1 trial set the stage for further studies that could significantly enhance treatment options for patients affected by EPI.

Who Are The Companies Competing Within The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd

Get The Full Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Which Region Dominates The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market By Market Share?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026, By The Business Research Company

Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Exocrine Pancreatic Insufficiency Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Acute Pancreatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Projected To Reach By 2030?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market has experienced robust growth in recent years. This market is projected to expand from $6.11 billion in 2025 to $6.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. Its historical growth can be attributed to elements such as the increasing prevalence of chronic pancreatitis, a heightened awareness of digestive disorders, limited access to specialized diagnostics, the adoption of nutritional supplements, and the expansion of home healthcare services.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $8.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. The projected increase during this period is driven by progress in personalized enzyme therapies, the incorporation of AI into diagnostics, an increasing need for non-invasive imaging, the widening availability of telehealth services, and a heightened emphasis on patient-focused nutritional management. Key trends expected during the forecast timeframe encompass sophisticated pancreatic enzyme replacement therapies, point-of-care diagnostic options, tailored nutritional management plans, non-invasive imaging methods for EPI, and the integration of telehealth into EPI management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What Significant Factors Are Influencing The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Expansion?

The anticipated rise in the number of individuals suffering from diabetes is projected to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes is defined as a long-term metabolic ailment characterized by persistently elevated blood sugar levels (hyperglycemia), stemming from the body’s inability to synthesize sufficient insulin or its inefficient utilization. EPI treatment, specifically pancreatic enzyme replacement therapy (PERT), is effective in enhancing nutrient absorption and can also improve glycemic control for those with both diabetes and EPI. For example, in June 2024, data from The National Health Service (NHS England), a publicly funded UK healthcare system, revealed that in 2023, the count of individuals identified with pre-diabetes by the NHS in England increased to 3,615,330, representing an 18% surge from 3,065,825 in 2022. Furthermore, among individuals below 40 years old, cases saw a nearly 25% rise, escalating from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing population affected by diabetes is a significant force driving the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The increasing occurrence of gastrointestinal illnesses is expected to stimulate the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Gastrointestinal diseases encompass a range of medical conditions impacting the digestive system, which includes the organs vital for food processing. These therapeutics and diagnostics for Exocrine pancreatic insufficiency (EPI) are essential for managing gastrointestinal diseases by addressing underlying enzyme deficiencies and facilitating proper nutrient digestion. As an illustration, in June 2023, Crohn’s and Colitis Canada, a non-profit organization based in Canada, estimated that over 322,600 Canadians were living with inflammatory bowel diseases (IBD) in 2023, constituting approximately 0.82% of the population. With the ongoing spread of IBD, it is predicted that around 470,000 Canadians will be affected by IBD by 2035, amounting to roughly 1.1% of the population, or 1 in every 91 people in the country. Thus, the escalating incidence of gastrointestinal diseases is poised to boost the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

How Are Segments Identified Within The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segment Framework?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

Which Trends Are Impacting The Progress Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Leading companies active in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are employing a strategic partnership strategy to boost technology integration and expand their market reach. A strategic partnership typically denotes a collaborative relationship between two or more entities, where they combine their assets, expertise, and endeavors to achieve shared goals or objectives. For instance, in February 2023, Codexis, Inc., a US-based protein engineering company, along with Nestlé Health Science, a Switzerland-based science of nutrition, disclosed preliminary results from their Phase 1 clinical trial of CDX-7108, an experimental therapy designed to treat exocrine pancreatic insufficiency (EPI). The outcomes from this Phase 1 trial set the stage for further studies that could significantly enhance treatment options for patients affected by EPI.

Who Are The Companies Competing Within The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd

Get The Full Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Which Region Dominates The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market By Market Share?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026, By The Business Research Company

Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Exocrine Pancreatic Insufficiency Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Acute Pancreatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has seen substantial growth in recent years. It is expected to expand from $6.11 billion in 2025 to $6.55 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. This historical growth can be attributed to an increase in the prevalence of chronic pancreatitis, greater awareness of digestive disorders, limited access to specialized diagnostics, the uptake of nutritional supplements, and the expansion of home healthcare services.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market is anticipated to show robust expansion in the coming years. It is projected to achieve a size of $8.97 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.2%. This expansion during the forecast period is attributable to advancements in personalized enzyme therapies, the integration of AI in diagnostics, a rising demand for non-invasive imaging, the broadening of telehealth services, and an increasing emphasis on patient-centric nutritional management. Key trends for the forecast period include advanced pancreatic enzyme replacement therapies, point-of-care diagnostic solutions, personalized nutritional management programs, non-invasive imaging techniques for epi, and the incorporation of telehealth into epi management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What Key Drivers Are Influencing The Growth Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

The rising prevalence of diabetes is anticipated to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market moving forward. Diabetes is defined as a chronic metabolic ailment marked by consistently elevated blood sugar levels (hyperglycemia) over an extended period, resulting from the body’s insufficient insulin production or its ineffective utilization. EPI treatment, primarily pancreatic enzyme replacement therapy (PERT), aids in enhancing nutrient absorption and can also assist in better glycemic control for individuals with diabetes and EPI. For instance, data from June 2024, provided by The National Health Service (NHS England), a UK-based publicly funded healthcare system, indicated that the count of individuals identified by the NHS in England with pre-diabetes reached 3,615,330 in 2023, representing an 18% increase from 3,065,825 in 2022. Furthermore, among those aged under 40, cases saw a surge of nearly 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Consequently, the growing number of people affected by diabetes is a key driver for the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

What Major Segment Divisions Exist Within The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

How Are Trends Shaping The Direction Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Leading businesses in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are utilizing a strategic partnership method to improve technology integration and expand their market reach. A strategic partnership usually indicates a cooperative relationship between two or more organizations where they merge their assets, knowledge, and efforts to achieve mutual goals or objectives. As an illustration, in February 2023, Codexis, Inc., a protein engineering company based in the US, and Nestlé Health Science, a nutrition science firm from Switzerland, disclosed interim outcomes from their Phase 1 clinical trial of CDX-7108, an experimental treatment intended for exocrine pancreatic insufficiency (EPI). The findings from this Phase 1 trial prepare the ground for future investigations that have the potential to considerably enhance therapeutic choices for EPI patients.

Which Companies Are Leading Innovation In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd

Read the full exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report here:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp

Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026, By The Business Research Company

Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Exocrine Pancreatic Insufficiency Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Acute Pancreatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market from 2026–2035 with trusted insights from The Business Research Company

What are the forecasted starting (2026) and ending (2030) market sizes for the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size has experienced robust expansion in recent years. This market is projected to increase from $6.11 billion in 2025 to $6.55 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.1%. The historical growth of the market is primarily due to factors such as the increasing prevalence of chronic pancreatitis, a rising awareness concerning digestive disorders, limited access to specialized diagnostics, the adoption of nutritional supplements, and the growth in home healthcare services.

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size is projected to experience robust expansion in the coming years. This market is anticipated to reach $8.97 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this growth during the forecast period include progress in personalized enzyme therapies, the incorporation of AI into diagnostics, an increasing need for non-invasive imaging, the widening scope of telehealth services, and a heightened emphasis on patient-focused nutritional management. Key trends shaping the forecast period encompass advanced pancreatic enzyme replacement therapies, point-of-care diagnostic solutions, tailored nutritional management programs, non-invasive imaging methods for epi, and the integration of telehealth into epi management.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

What Drivers Are Supporting Technological Adoption In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

The growing population affected by diabetes is projected to stimulate the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Diabetes is defined as a long-term metabolic ailment marked by sustained elevated blood sugar levels (hyperglycemia), arising from the body’s failure to produce sufficient insulin or utilize it effectively. Exocrine pancreatic insufficiency (EPI) therapy, which includes pancreatic enzyme replacement therapy (PERT), can enhance nutrient absorption for individuals with both diabetes and EPI, and also aid in better glycemic control for diabetic patients. As an illustration, in June 2024, The National Health Service (NHS England), a UK public healthcare system, reported that the number of people identified with pre-diabetes in England climbed to 3,615,330 in 2023, representing an 18% rise from 3,065,825 in 2022. Furthermore, for those under 40, cases increased by nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising incidence of diabetes among the populace is propelling the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

Which Segments Are Contributing To The Growth Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

What Trends Are Driving The Growth Trajectory Of The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Leading firms within the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are increasingly employing strategic partnerships to boost technological integration and broaden their market presence. Such partnerships involve cooperative arrangements between multiple entities, pooling their collective resources, knowledge, and endeavors to attain shared aims. An illustrative example occurred in February 2023, when Codexis, Inc., a US-based protein engineering firm, and Nestlé Health Science, a nutrition science company based in Switzerland, disclosed preliminary outcomes from their Phase 1 clinical trial for CDX-7108, an experimental treatment designed for exocrine pancreatic insufficiency (EPI). These Phase 1 trial results create opportunities for subsequent research that holds the potential to substantially enhance treatment alternatives for individuals afflicted with EPI.

Who Are The Core Companies Influencing Trends In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Abbott Laboratories, Metagenics LLC, Chiesi Farmaceutici S.p.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Bioserv Diagnostics Gmbh, Aptalis Pharma Inc., EagleBiosciences Inc., ScheBo Biotech AG, Solvay S.A., Codexis Inc., ChiRhoClin Inc., Alcresta Therapeutics Inc., Cilian AG, First Wave BioPharma Inc., Laboratory Corporation of America Holdings, Organon, Vivus Inc., Anthera Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Which Regions Are Projected To Dominate The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market In The Coming Years?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2025. The regions covered in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp

Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2026, By The Business Research Company

Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Exocrine Pancreatic Insufficiency Market Report 2026

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Acute Pancreatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Now And By 2029?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market has experienced significant growth over recent years. It is projected to expand from $5.69 billion in 2024 to $6.11 billion in 2025, at a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to the increased prevalence of underlying conditions, advancements in diagnostic tools, pharmaceutical developments, and rising global healthcare access.

The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market size is anticipated to expand significantly in the upcoming years. It is projected to reach $8.21 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.7%. The expansion during this forecast period is attributable to aspects like telemedicine and remote monitoring, data analytics and AI, patient education and support, as well as changes in regulatory and reimbursement policies. Noteworthy trends for the forecast period include personalized treatment approaches, the development of new therapies, minimally invasive diagnostics, and collaborative care models.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

Which Long-Term Drivers Are Expected To Sustain The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

The growing population affected by diabetes is anticipated to drive the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in the future. Diabetes is defined as a long-term metabolic condition marked by elevated blood sugar levels (hyperglycemia) extending over an extended duration, arising from the body’s deficiency in producing sufficient insulin or its ineffective utilization of the insulin it generates. Pancreatic enzyme replacement therapy (PERT), central to EPI treatment, can facilitate better nutrient absorption for individuals experiencing both diabetes and EPI, and additionally, it can contribute to enhanced glycemic control in diabetic patients. As an illustration, data released in June 2024 by The National Health Service (NHS England), a publicly funded healthcare system in the UK, revealed that in 2023, the count of individuals identified by the NHS in England with pre-diabetes climbed to 3,615,330. This represented an 18% surge from the 3,065,825 recorded in 2022. Furthermore, cases among those aged under 40 experienced a near 25% increase, rising from 173,166 in 2022 to 216,440 in 2023. Consequently, the expanding population affected by diabetes is propelling the advancement of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

How Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Classified By Different Segments?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

What Current And Upcoming Trends Are Shaping The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Key companies within the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are increasingly adopting a strategic partnership model to improve technology integration and expand their market presence. A strategic partnership generally signifies a cooperative arrangement between multiple organizations that combine their resources, expertise, and efforts to achieve common objectives. For example, in February 2023, Codexis, Inc., a US-based protein engineering company, and Nestlé Health Science, a Switzerland-based science of nutrition company, disclosed interim results from their Phase 1 clinical trial involving CDX-7108, an investigational therapy developed for treating exocrine pancreatic insufficiency (EPI). The outcomes of this Phase 1 trial lay the groundwork for future studies that could significantly enhance treatment possibilities for individuals living with EPI.

Who Are The Primary Market Leaders In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp

Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market 2025, By The Business Research Company

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Irritable Bowel Syndrome Ibs Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Big Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Today And What Is Its Future Size?

In recent years, there has been a robust expansion in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. This surge is anticipated to continue, rising from $5.69 billion in 2024 to $6.11 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.3%. The progression observed in the historic phase can be connected to the augmented incidence of base conditions, improvement in diagnostic instruments, advancements in pharmaceuticals, and an increase in global healthcare accessibility.

Significant expansion is anticipated for the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market in the coming years, with it projected to reach a size of “$8.21 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 7.7%. The forecast period’s growth can be credited to factors such as patient education and support, regulatory shifts and reimbursement policies, as well as the advancement of telemedicine, remote monitoring, data analytics and artificial intelligence. Other key trends expected to impact the market in the forecast period include the rise of personalized treatment methods, the introduction of new therapies, less invasive diagnostic procedures, and integrative care models.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp

Which Growth Drivers Are Shaping The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Outlook?

The surge in diabetes cases is forecasted to stimulate expansion in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes is a long-term metabolic disorder identified by enduring high blood sugar levels (hyperglycemia), caused by inadequate insulin production or improper insulin utilization by the body. EPI therapy, especially pancreatic enzyme replacement therapy (PERT), is beneficial for nutrient assimilation in diabetic and EPI patients, besides enhancing glycemic control. For example, The National Health Service (NHS England), a UK-based government-funded healthcare organization, revealed that the figure of people identified with pre-diabetes escalated to 3,615,330 in June 2024, an 18% rise from 3,065,825 in 2023. Remarkably, among those below 40 years, cases soared nearly 25%, moving up from 173,166 in 2022 to 216,440 in 2023. Consequently, the rising diabetes count is fuelling the enlargement of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.

How Is The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Categorized Across Applications And Types?

The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –

1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach

2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning

3) By Drug Type: Generic, Branded

4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels

5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users

Subsegments:

1) By Nutritional Management: Dietary Modifications, Nutritional Supplements

2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations

3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs

How Are Market Trends Influencing Competition In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Leading firms in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are employing a strategic alliance strategy to bolster technology integration and broaden their market footprint. A strategic alliance typically involves the fusion of resources, skills, and efforts of two or more companies in pursuit of mutual goals or objectives. For example, in February 2023, Codexis, Inc., a US-based firm specialized in protein engineering, and Nestlé Health Science, a Swiss firm focused on the science of nutrition, unveiled interim outcomes from their Phase 1 clinical trial of CDX-7108, a potential treatment for exocrine pancreatic insufficiency (EPI). These Phase 1 trial outcomes set the stage for further investigations that could markedly enhance treatment possibilities for patients afflicted with EPI.

Who Are The Primary Market Leaders In The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report

What Are The Emerging Regional Trends Driving The Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?

North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=12992&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model